Abstract
Purpose
Two studies were conducted to compare the pharmacokinetics and tolerability of exemestane in postmenopausal subjects with various degrees of impairment of hepatic or renal function with those in healthy postmenopausal subjects.
Methods
All subjects were postmenopausal females. In study 1, nine subjects had normal hepatic function (Child-Pugh grade A), and nine had moderately (grade B) and eight severely (grade C) impaired hepatic function. In study 2, six subjects had normal renal function, and six moderately (creatinine clearance, CrCL, 30–60 ml/min per 1.73 m2) and seven severely (CrCL <29 ml/min per 1.73 m2) impaired renal function. Each subject took a single oral dose of 25 mg exemestane. Samples of plasma (to 168 h after dosing) and urine (to 72 h in study 1, or 96 h in study 2) were taken for pharmacokinetic analysis. Safety and tolerability were assessed by monitoring vital signs, laboratory safety tests, ECG and adverse events.
Results
Exposure to exemestane was increased two- to threefold in patients with hepatic impairment. Thus, the geometric mean AUC0–∞ values were 41.71 (90% CI 32.2 to 54.0), 99.02 (76.5 to 128.2) and 118.59 ng·h/ml (90.2 to 156.0) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively (P<0.01). Cmax also increased twofold. Compared with healthy subjects, patients with hepatic impairment had lower apparent oral clearance and apparent volume of distribution of exemestane. Renal impairment was also associated with two- to threefold increases in AUC0–∞: 34.64 (90% CI 23.9 to 50.2), 94.10 (64.9 to 136.4) and 65.52 ng·h/ml (46.5 to 92.4) in healthy subjects, and in patients with moderate and severe hepatic impairment, respectively (P<0.05). Cmax did not change significantly. Apparent oral clearance was directly correlated with CrCL (r 2=0.43). Exemestane was tolerated well, with no safety concerns.
Conclusions
Oral clearance of exemestane was reduced in the presence of significant hepatic or renal disease. However, in view of the relatively large safety margin and the mild nature of the side effects of exemestane, the therapeutic implications of these changes in pharmacokinetics are considered minor and of no clinical significance.
Similar content being viewed by others
References
Clemett D, Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
Dank M (2002) The role of Aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res 8:87
Geigy Scientific Tables, vol. 3. Ciba-Geigy, Basle, p 329
Henderson JC, Canellos GP (1980) Cancer of the breast: the past decade (part 1). N Engl J Med 302:17
Lombardi P (2002) Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim Biophys Acta 1587:326
Machin D, Campbell MJ (1987) Statistical tables for the design of clinical trials. Blackwell Scientific, Oxford, pp 79–83
Paridaens R, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K (1998) Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 9:675
Persiani S, Broutin F, Cicioni P, Stefanini P, Strolin Benedetti M (1996) Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 4:331
Poggesi I, Jannuzzo MG, diSalle E, Piscitelli G, Rocchetti M, Spinelli R, Broutin F, Ornati G, Massimini G (1999) Effect of food on pharmacokinetics (PK) and pharmacodynamics (PD) of exemestane (Aromasin, EXE). 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, 15–18 May 1999
Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646
Spinelli R, Jannuzzo MG, Poggesi I, Frevola L, Broutin F, Cicioni P, Marrari P, LeCoz F (1999) Pharmacokinetics (PK) of Aromasin (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV) (abstract 1185). Proc ECCO. Eur J Cancer 35(S4):S295
Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G (1997) Third line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicenter multinational study. Eur J Cancer 33:1767
Yoshitani T, Yagi H, Inotsume N, Yasuhara M (2002) Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 25:1077–1083
Acknowledgements
The study sponsor was Pharmacia, Nerviano, Italy, which provided financial and material support. The authors would like to thank Kirsteen Donaldson, DM, who provided assistance with the preparation of the manuscript, and Patrick Duchene, PhD (ADME Bioanalysis), François Ducret, MD (Centre Hospitalier d’Annecy), Angelika Weil, MD (Apex Research), and Violette Leclerc, MD (Aster-Cephac) for their contribution and support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jannuzzo, M.G., Poggesi, I., Spinelli, R. et al. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 53, 475–481 (2004). https://doi.org/10.1007/s00280-004-0774-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0774-5